TS
KNTE

Thomas Steyer’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Thomas Steyer’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250,000
Closed -$7.79M – 320
2021
Q1 		$7.79M Hold
250,000
– – 0.04% 156
2020
Q4 		$9.95M Buy
+250,000
New +$10M 0.06% 108

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Thomas Steyer's KNTE Position: Q2 2021 in Review

Thomas Steyer sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2021, closing a stake of 250,000 shares — an estimated $7.79M sold.

Thomas Steyer first reported a position in KNTE in Q4 2020 and held it in 2 quarters. The position peaked at $9.95M in Q4 2020. 62 funds tracked by Wall St. Rank hold KNTE as of Q2 2021.

  • Thomas Steyer reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Thomas Steyer sold 250,000 Kinnate Biopharma Inc. Common Stock shares in Q2 2021, an estimated $7.79M.
  • Thomas Steyer first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Thomas Steyer's Kinnate Biopharma Inc. Common Stock position peaked at $9.95M in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.